2022-06-30 17:45 Regulatory
Biovica, active in cancer diagnostics, today announces that the company’s CFO and deputy CEO Cecilia Driving today has submitted her letter of resignation. A process to recruit a replacement is immediately initiated. Cecilia Driving, who has been...
2022-06-30 08:00 Regulatory Annual
Annual report for the financial year 2021/2022 for Biovica International AB is published today on our website. Financials – Biovica Contact Anders Rylander, CEO Phone: +46-18-444 48 35 E-mail: anders.rylander@biovica.com Cecilia Driving, EVP CFO...
2022-06-16 08:00 Regulatory Interim
Significant events during the fourth quarter Significant events after the end of the period Audiocast: When: 16 June 2022 at 15.00 CET Where: https://tv.streamfabriken.com/biovica-international-q4-2021-2022 Phone numbers: SE: +46856642692, DK: +4578723252...
2022-06-13 10:00 Regulatory
Biovica today announced that the company’s blood test DiviTum®TKa was highlighted in an oral presentation on June 6th at the ASCO Annual Meeting from the BioItaLEE trial. The study results suggest that TKa can predict patients’ response...
2022-05-09 13:15 Regulatory
Biovica, active in cancer diagnostics, today announces that the company's blood test DiviTum®TKa will be included in one oral presentation and two abstracts/posters, at the world's largest cancer congress, ASCO Annual Meeting, June 3-7...
2022-04-28 18:00 Regulatory
Biovica, active in cancer diagnostics, today announces that the company has submitted its updated 510(k)-application to the U.S. Food and Drug Administration (FDA) to receive marketing authorization for the blood-based biomarker assay DiviTum®TKa...
2022-04-28 08:00 Regulatory
Biovica, active in cancer diagnostics, will host a Capital Markets Day on Tuesday May 17, 2022, from 14.00 to 16.30. Biovica is approaching market launch of DiviTum®TKa in the US for the monitoring of metastatic breast cancer treatments. Today, DiviTum®TKa...
2022-03-22 09:30 Regulatory
Biovica, active in cancer diagnostics, today announced that positive results on CDK 4/6 standard therapy from a clinical study at the University of Nebraska Medical Center and Washington University School of Medicine, US, is published in npj Breast Cancer...
2022-03-15 08:00 Regulatory Interim
Significant events during the third quarter Significant events after the end of the period Audiocast: When: 15 March 2022 at 3 PM CET Where: https://tv.streamfabriken.com/biovica-international-q3-2021-2022 Phone numbers: SE: +46850558356, DK: +4582333194...
2022-03-14 18:55 Regulatory
Biovica, active in cancer diagnostics, today announces that the company will establish its own US CLIA lab for the launch of DiviTum®TKa on the US market. Biovica aims to have its lab operational and CLIA certified during third quarter 2022. Biovica...

>4,500

Numbers of patients in studies

28

Publications

22

Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program

No